Elissa M Ozanne

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis
    Elissa M Ozanne
    Institute for Technology Assessment at Massachusetts General Hospital, Department of Radiology, Harvard Medical School, 101 Merrimac Street, 10th Floor, Boston, MA 02114 4724, USA
    Cancer Epidemiol Biomarkers Prev 13:2043-52. 2004
  2. ncbi Breast cancer risk assessment and prevention: a framework for shared decision-making consultations
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Breast J 12:103-13. 2006
  3. ncbi Pilot trial of a computerized decision aid for breast cancer prevention
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Breast J 13:147-54. 2007
  4. ncbi Characterizing the impact of 25 years of DCIS treatment
    Elissa M Ozanne
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Breast Cancer Res Treat 129:165-73. 2011
  5. ncbi Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model
    Elissa M Ozanne
    Institute for Technology Assessment and Health Decision Research Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 27:214-9. 2009
  6. ncbi Breast cancer prevention: patient decision making and risk communication in the high risk setting
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Breast J 16:38-47. 2010
  7. ncbi Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
    Laura J Esserman
    Deptartment of Surgery, University of California San Francisco Medical Center, San Francisco, CA, USA
    Breast Cancer Res 7:R1153-8. 2005
  8. ncbi Is there a role for decision aids in advanced breast cancer?
    Karen R Sepucha
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Med Decis Making 29:475-82. 2009
  9. ncbi Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis
    Kathryn P Lowry
    Massachusetts General Hospital Institute for Technology Assessment, Boston, Massachusetts, USA
    Cancer 118:2021-30. 2012
  10. ncbi Which risk model to use? Clinical implications of the ACS MRI screening guidelines
    Elissa M Ozanne
    University of California, San Francisco, CA, USA
    Cancer Epidemiol Biomarkers Prev 22:146-9. 2013

Collaborators

Detail Information

Publications17

  1. ncbi Evaluation of breast cancer risk assessment techniques: a cost-effectiveness analysis
    Elissa M Ozanne
    Institute for Technology Assessment at Massachusetts General Hospital, Department of Radiology, Harvard Medical School, 101 Merrimac Street, 10th Floor, Boston, MA 02114 4724, USA
    Cancer Epidemiol Biomarkers Prev 13:2043-52. 2004
    ..Assess the effectiveness and cost-effectiveness of using biomarkers and risk assessment tools to stratify women for breast cancer preventive interventions...
  2. ncbi Breast cancer risk assessment and prevention: a framework for shared decision-making consultations
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Breast J 12:103-13. 2006
    ..The framework is intended to encourage a shared decision-making approach to prevention consultations, a method for researchers to increase accrual to trials, and to more quickly incorporate new findings into the routine of practice...
  3. ncbi Pilot trial of a computerized decision aid for breast cancer prevention
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Breast J 13:147-54. 2007
    ..The tendency for the decision choices and knowledge scores to return to baseline at follow-up suggests the need for initial and ongoing prevention decision support...
  4. ncbi Characterizing the impact of 25 years of DCIS treatment
    Elissa M Ozanne
    Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    Breast Cancer Res Treat 129:165-73. 2011
    ..Given the tradeoff illustrated by our model, we must reevaluate the assumption that DCIS is a short-term obligate precursor of invasive cancer and instead focus on further exploration of the true natural history of DCIS...
  5. ncbi Sensitivity to input variability of the Adjuvant! Online breast cancer prognostic model
    Elissa M Ozanne
    Institute for Technology Assessment and Health Decision Research Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
    J Clin Oncol 27:214-9. 2009
    ..Because comorbidity is strongly and independently associated with survival, this study tested the hypothesis that Adjuvant! predictions would be sensitive to comorbidity inputs...
  6. ncbi Breast cancer prevention: patient decision making and risk communication in the high risk setting
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Breast J 16:38-47. 2010
    ....
  7. ncbi Tamoxifen may prevent both ER+ and ER- breast cancers and select for ER- carcinogenesis: an alternative hypothesis
    Laura J Esserman
    Deptartment of Surgery, University of California San Francisco Medical Center, San Francisco, CA, USA
    Breast Cancer Res 7:R1153-8. 2005
    ....
  8. ncbi Is there a role for decision aids in advanced breast cancer?
    Karen R Sepucha
    Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
    Med Decis Making 29:475-82. 2009
    ..A diagnosis of metastatic breast cancer (BC) forces patients and providers to make difficult treatment decisions...
  9. ncbi Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis
    Kathryn P Lowry
    Massachusetts General Hospital Institute for Technology Assessment, Boston, Massachusetts, USA
    Cancer 118:2021-30. 2012
    ..Although breast cancer screening with mammography and magnetic resonance imaging (MRI) is recommended for breast cancer-susceptibility gene (BRCA) mutation carriers, there is no current consensus on the optimal screening regimen...
  10. ncbi Which risk model to use? Clinical implications of the ACS MRI screening guidelines
    Elissa M Ozanne
    University of California, San Francisco, CA, USA
    Cancer Epidemiol Biomarkers Prev 22:146-9. 2013
    ..Our results indicate that these models identify very different populations, implying that the ACS guidelines deserve further development and consideration...
  11. ncbi Identification and management of women at high risk for hereditary breast/ovarian cancer syndrome
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
    Breast J 15:155-62. 2009
    ..These early results indicate that the number of patients identified for risk assessment has increased dramatically and that the care of these patients is more efficient and likely more effective...
  12. ncbi Cost-effectiveness of breast MR imaging and screen-film mammography for screening BRCA1 gene mutation carriers
    Janie M Lee
    Department of Radiology, Institute for Technology Assessment, Division of Hematology Oncology, Department of Medicine, Massachusetts General Hospital, 101 Merrimac St, 10th Floor, Boston, MA 02114, USA
    Radiology 254:793-800. 2010
    ..c) RSNA, 2010 Supplemental material: http://radiology.rsna.org/lookup/suppl/doi:10.1148/radiol.09091086/-/DC1...
  13. ncbi Staging MR lymphangiography of the axilla for early breast cancer: cost-effectiveness analysis
    Pari V Pandharipande
    Department of Radiology, Institute for Technology Assessment, Massachusetts General Hospital, 101 Merrimac St, 10th Fl, Boston, MA 02114, USA
    AJR Am J Roentgenol 191:1308-19. 2008
    ..The purpose of this study was to compare the cost-effectiveness of MR lymphangiography-based strategies with that of sentinel lymph node (SLN) biopsy alone in the axillary staging of early breast cancer...
  14. ncbi Doctor-patient communication about advance directives in metastatic breast cancer
    Elissa M Ozanne
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, USA
    J Palliat Med 12:547-53. 2009
    ..This study examined whether or not patients with metastatic breast cancer had advance directives, and if so, with whom they discussed written plans for end-of-life decisions...
  15. ncbi How to define and measure concordance between patients' preferences and medical treatments: A systematic review of approaches and recommendations for standardization
    Karen Sepucha
    Health Decision Research Unit, Massachusetts General Hospital MGH, Harvard Medical School HMS, 50 Staniford Street, Suite 936, Boston, MA 02114, USA
    Patient Educ Couns 78:12-23. 2010
    ..The purpose is to systematically review the methods used to calculate the association between patients' preferences and treatment choices and to present a set of recommendations for definition and measurement of this concept...
  16. ncbi Patient preferences for the chemoprevention of colorectal cancer
    Chin Hur
    Institute for Technology Assessment, Massachusetts General Hospital, Boston, MA, USA
    Dig Dis Sci 54:2207-14. 2009
    ..These data serve to inform physicians and researchers regarding the variability and factors that affect patient preferences for CRC chemoprevention...
  17. ncbi Implementing breast cancer decision aids in community sites: barriers and resources
    Kerry A Silvia
    Massachusetts General Hospital, Boston, MA 02114, USA
    Health Expect 11:46-53. 2008
    ..To assess the feasibility of implementing four patient decision aids (PtDAs) for early stage breast cancer treatment decisions into routine clinical care in community settings...